The capital infusion is earmarked to facilitate a $1 billion debt reduction, a key milestone in FMC’s ongoing recovery plan. By offloading this financial burden, the Philadelphia-based company intends to pivot toward accelerating its R&D pipeline and commercializing new proprietary molecules. Pierre Brondeau, chairman and CEO of FMC, stated the board views this partnership as the most viable path forward for shareholders following a comprehensive evaluation process that began in February 2026.

For Tessenderlo Group, the move serves as a cornerstone addition to its agricultural platform. CEO Luc Tack noted that the investment reflects a broader strategy of acquiring minority positions in high-quality companies with significant long-term growth potential. The deal follows a series of aggressive financial maneuvers by FMC over recent months, including a $1.2 billion high-yield bond offering, the sale of its India commercial business, and a strategic supply agreement with Corteva. The transaction remains subject to customary regulatory approvals.